|
|
||||||||
1 National Institute of Environmental Health Sciences, Research Triangle Park 27709; 2 Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710; and 3 Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104
To investigate the role of 12-lipoxygenase in preconditioning, we examined whether hearts lacking the "leukocyte-type" 12-lipoxygenase (12-LOKO) would be protected by preconditioning. In hearts from wild-type (WT) and 12-LOKO mice, left ventricular developed pressure (LVDP) and 31P NMR were monitored during treatment (±preconditioning) and during global ischemia and reperfusion. Postischemic function (rate-pressure product, percentage of initial value) measured after 20 min of ischemia and 40 min of reperfusion was significantly improved by preconditioning in WT hearts (78 ± 12% in preconditioned vs. 44 ± 7% in nonpreconditioned hearts) but not in 12-LOKO hearts (47 ± 7% in preconditioned vs. 33 ± 10% in nonpreconditioned hearts). Postischemic recovery of phosphocreatine was significantly better in WT preconditioned hearts than in 12-LOKO preconditioned hearts. Preconditioning significantly reduced the fall in intracellular pH during sustained ischemia in both WT and 12-LOKO hearts, suggesting that attenuation of the fall in pH during ischemia can be dissociated from preconditioning-induced protection. Necrosis was assessed after 25 min of ischemia and 2 h of reperfusion using 2,3,5-triphenyltetrazolium chloride. In WT hearts, preconditioning significantly reduced the area of necrosis (26 ± 4%) compared with nonpreconditioned hearts (62 ± 10%) but not in 12-LOKO hearts (85 ± 3% in preconditioned vs. 63 ± 11% in nonpreconditioned hearts). Preconditioning resulted in a significant increase in 12(S)-hydroxyeicosatetraenoic acid in WT but not in 12-LOKO hearts. These data demonstrate that 12-lipoxygenase is important in preconditioning.
myocardial ischemia; infarction; prostaglandins; nuclear magnetic resonance
This article has been cited by other articles:
![]() |
Y. M. Tsutsumi, H. H. Patel, D. Huang, and D. M. Roth Role of 12-lipoxygenase in volatile anesthetic-induced delayed preconditioning in mice Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H979 - H983. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Gross, J. R. Falck, E. R. Gross, M. Isbell, J. Moore, and K. Nithipatikom Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited Cardiovasc Res, October 1, 2005; 68(1): 18 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Schafer, D. N. Sehrt, M. Kamler, H. Jakob, and H.-A. Lehr Paradoxical attenuation of leukocyte rolling in response to ischemia- reperfusion and extracorporeal blood circulation in inflamed tissue Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H330 - H335. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Kong, N. Bodyak, P. Yue, Z. Liu, J. Brown, S. Izumo, and P. M. Kang Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats Physiol Genomics, March 21, 2005; 21(1): 34 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Seubert, B. Yang, J. A. Bradbury, J. Graves, L. M. Degraff, S. Gabel, R. Gooch, J. Foley, J. Newman, L. Mao, et al. Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K+ Channels and p42/p44 MAPK Pathway Circ. Res., September 3, 2004; 95(5): 506 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zuo, F. L. Christofi, V. P. Wright, S. Bao, and T. L. Clanton Lipoxygenase-dependent superoxide release in skeletal muscle J Appl Physiol, August 1, 2004; 97(2): 661 - 668. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tong, H. A. Rockman, W. J. Koch, C. Steenbergen, and E. Murphy G Protein-Coupled Receptor Internalization Signaling Is Required for Cardioprotection in Ischemic Preconditioning Circ. Res., April 30, 2004; 94(8): 1133 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Murphy Primary and Secondary Signaling Pathways in Early Preconditioning That Converge on the Mitochondria to Produce Cardioprotection Circ. Res., January 9, 2004; 94(1): 7 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Patel, R. M. Fryer, E. R. Gross, R. A. Bundey, A. K. Hsu, M. Isbell, L. O.V. Eusebi, R. V. Jensen, S. R. Gullans, P. A. Insel, et al. 12-Lipoxygenase in Opioid-Induced Delayed Cardioprotection: Gene Array, Mass Spectrometric, and Pharmacological Analyses Circ. Res., April 4, 2003; 92(6): 676 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schulz, M. V Cohen, M. Behrends, J. M Downey, and G. Heusch Signal transduction of ischemic preconditioning Cardiovasc Res, November 1, 2001; 52(2): 181 - 198. [Full Text] [PDF] |
||||
![]() |
P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |